TY - JOUR
T1 - Characterization of a chlorambucil-resistant human ovarian carcinoma cell line overexpressing glutathione S-transferase μ
AU - Horton, Julie K.
AU - Roy, Gargi
AU - Piper, John T.
AU - Van Houten, Bennett
AU - Awasthi, Yogesh C.
AU - Mitra, Sankar
AU - Alaoui-Jamali, Moulay A.
AU - Boldogh, Istvan
AU - Singhal, Sharad S.
PY - 1999/8/15
Y1 - 1999/8/15
N2 - Ovarian carcinoma cells 10-fold resistant to the alkylating agent chlorambucil (CBL) were isolated after repeated exposure of the parent cells to gradually escalating concentrations of the drug. The resistant variant, A2780(100), was highly cross-resistant (9-fold) to melphalan and showed lower-level resistance to other cross-linking agents. The resistant A2780(100) cells had almost 5-fold higher glutathione S-transferase (GST) activity than the parental A2780 cells with 1-chloro-2,4-dinitrobenzene (CDNB) as substrate. The π-class GST(s) was the major isoform(s) in both cell lines. However, the resistant A2780(100) cells had at least 11-fold higher GST μ as compared with the parental cells, in which this isoform was barely detectable. A significant induction of GST μ was observed in A2780 cells, but not in the resistant cells, 18 hr after a single exposure to 100 μM CBL. The induction of GST μ by CBL was both time- and concentration-dependent. Assays of the conjugation of CBL with GSH showed that the human μ-class GST had 3.6- and 5.2-fold higher catalytic efficiency relative to the π- and α-class GSTs, respectively. This difference was reflected in the relatively higher (about 6-fold) efficiency of CBL conjugation in A2780(100) cells as compared with the parental cells. These results have demonstrated for the first time a near-linear correlation between CBL resistance and overexpression of μ-class GSTs and suggest that this overexpression maybe responsible, at least in part, for the acquired resistance of ovarian carcinoma cells to CBL, and possibly the other bifunctional alkylating agents. Consistent with this hypothesis, we found evidence for decreased formation of DNA lesions in A2780(100) compared with the drug-sensitive A2780 cells after exposure to CBL. Copyright (C) 1999 Elsevier Science Inc.
AB - Ovarian carcinoma cells 10-fold resistant to the alkylating agent chlorambucil (CBL) were isolated after repeated exposure of the parent cells to gradually escalating concentrations of the drug. The resistant variant, A2780(100), was highly cross-resistant (9-fold) to melphalan and showed lower-level resistance to other cross-linking agents. The resistant A2780(100) cells had almost 5-fold higher glutathione S-transferase (GST) activity than the parental A2780 cells with 1-chloro-2,4-dinitrobenzene (CDNB) as substrate. The π-class GST(s) was the major isoform(s) in both cell lines. However, the resistant A2780(100) cells had at least 11-fold higher GST μ as compared with the parental cells, in which this isoform was barely detectable. A significant induction of GST μ was observed in A2780 cells, but not in the resistant cells, 18 hr after a single exposure to 100 μM CBL. The induction of GST μ by CBL was both time- and concentration-dependent. Assays of the conjugation of CBL with GSH showed that the human μ-class GST had 3.6- and 5.2-fold higher catalytic efficiency relative to the π- and α-class GSTs, respectively. This difference was reflected in the relatively higher (about 6-fold) efficiency of CBL conjugation in A2780(100) cells as compared with the parental cells. These results have demonstrated for the first time a near-linear correlation between CBL resistance and overexpression of μ-class GSTs and suggest that this overexpression maybe responsible, at least in part, for the acquired resistance of ovarian carcinoma cells to CBL, and possibly the other bifunctional alkylating agents. Consistent with this hypothesis, we found evidence for decreased formation of DNA lesions in A2780(100) compared with the drug-sensitive A2780 cells after exposure to CBL. Copyright (C) 1999 Elsevier Science Inc.
KW - Chlorambucil
KW - Drug resistance
KW - Glutathione S-transferase
KW - Ovarian carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0033567422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033567422&partnerID=8YFLogxK
U2 - 10.1016/S0006-2952(99)00142-2
DO - 10.1016/S0006-2952(99)00142-2
M3 - Article
C2 - 10413308
AN - SCOPUS:0033567422
VL - 58
SP - 693
EP - 702
JO - Biochemical pharmacology
JF - Biochemical pharmacology
SN - 0006-2952
IS - 4
ER -